Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals Inc.

The latest announcement is out from Madrigal Pharmaceuticals ( ($MDGL) ). On January 29, 2026, Madrigal Pharmaceuticals and Roche amended their lon...

Madrigal Gains Expanded Patent Control Over Rezdiffra With Roche

Insiders have been trading these 5 stocks: (($MDGL)), (($CLNN)), (($COR)), (($SQNS)) and (($FOLD)). Here is a breakdown of their recent trades and ...

Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Madrigal Pharmaceuticals, with a price targe...

Current Quarter	$0.01	Next Quarter	$0.35
Current Year	$-10.32	Next Year	$2.18
QoQ Growth	+3400.0%	YoY Growth	+121.1%
3Y EPS CAGR	-14.4%	Target Price	$649.38
Consensus	Buy	Upside	+36.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MDGL	$475.70	-2.87%	233.34K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MDGL	$475.70	-2.9%	233.34K
3
4
5
6

MDGL

MDGL

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Madrigal Pharmaceuticals Inc. Data in Excel

Get Madrigal Pharmaceuticals Inc. Data in Excel